RxDoctor Payments Data

Timothy Cox, MD

Hematology & Oncology · Petoskey, MINPI 1437260650

Payments from drug & device makers

$23,359in general payments, 2019–2025

Across 363 payments — averaging $64.35 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Janssen Research & Development, LLC$14K
  • Astellas Pharma US Inc$826
  • Novartis$689
  • Johnson & Johnson$530
  • Tempus AI, Inc$484
  • Gilead$413
  • plus $6K from 54 others

What the payments were for

  • Food & beverage$7,65186%
  • Education$1,28514%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Janssen Research & Development, LLC7$14,423
Astellas Pharma US Inc19$826
Novartis45$689
Johnson & Johnson(2 entities)18$530
Tempus AI, Inc13$484
Gilead20$413
Incyte Corporation13$369
Genentech USA, Inc.18$356
E.r. Squibb & Sons, L.L.C.11$339
AstraZeneca(2 entities)13$315
Pfizer15$298
Seagen Inc.7$288
Takeda Pharmaceuticals U.S.A., Inc.12$277
Merck10$250
Sanofi9$242
Eisai Inc.9$210
Lilly USA, LLC6$201
Sirtex Medical Inc1$193
Tersera Therapeutics LLC7$181
Daiichi Sankyo Inc.8$176
Bristol Myers Squibb8$167
Array Biopharma Inc6$127
Ipsen Biopharmaceuticals, Inc3$124
Jazz Pharmaceuticals Inc.5$119
Intuitive Surgical1$99
Pharmaessentia USA Corporation4$92
Bayer4$82
AVEO Pharmaceuticals, Inc.5$79
Janssen Scientific Affairs, LLC2$79
Beigene USA, Inc.3$78
Puma Biotechnology, Inc.4$72
Regeneron Healthcare Solutions, Inc.3$66
Pharmacyclics LLC, An Abbvie Company1$65
Medical Device Business Services, Inc.1$58
Rigel Pharmaceuticals, Inc.3$54
EMD Serono, Inc.3$54
AbbVie3$52
GSK2$47
Sobi, Inc2$43
Recordati_rare_diseases_inc.2$42
Taiho Oncology, Inc.2$40
Agios Pharmaceuticals, Inc.2$39
Blueprint Medicines Corporation2$38
Springworks Therapeutics, Inc.2$38
Coherus Oncology, Inc.2$37
Pharmacosmos Therapeutics Inc.2$35
Servier Pharmaceuticals LLC2$35
Sun Pharmaceutical Industries Inc.1$32
ADC Therapeutics America, Inc.1$31
Mirati Therapeutics, Inc.2$30
Inari Medical, Inc.1$26
Apellis Pharmaceuticals, Inc.1$24
Spectrum Pharmaceuticals Inc.1$23
Dendreon Pharmaceuticals LLC1$21
Myriad Genetic Laboratories, Inc.1$20
Karyopharm Therapeutics Inc.1$20
Progenics Pharmaceuticals, Inc.1$19
Verastem, Inc.1$19
G1 Therapeutics, Inc.1$19
CTI Biopharma Corp.1$19

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$23,359 in reported general payments places this provider in the 75th percentile of 282 hematology & oncology providers in Michigan.

See all hematology & oncology providers in Michigan

Medicare billing

Part B allowed, 2024
$59,638
Medicare patients
286
Services billed
721

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
RevlimidLenalidomide26$513,293
JakafiRuxolitinib Phosphate25$338,006
XtandiEnzalutamide18$224,418
Lenalidomide13$185,079
Abiraterone Acetate23$98,693
EliquisApixaban29$18,695
Exemestane68$11,008
Anastrozole118$4,943
Imatinib Mesylate13$2,645
Letrozole78$1,907
Prochlorperazine Maleate76$1,293
Hydrocodone-AcetaminophenHydrocodone/Acetaminophen33$1,281
Hydroxyurea34$1,101
Dexamethasone48$796
Tamoxifen Citrate37$792

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Bristol Myers SquibbRevlimid$167$513,29326 claims
Incyte CorporationJakafi$369$338,00625 claims
Astellas Pharma US IncXtandi$826$224,41818 claims
Janssen Scientific Affairs, LLCAbiraterone Acetate$79$98,69323 claims
PfizerEliquis$298$18,69529 claims
Lilly USA, LLCOlanzapine$201$8043 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 75th percentile of 282 hematology & oncology providers in Michigan.

Other hematology & oncology in Petoskey

See the full list for Michigan

Where these figures come from

Is this you, or does something look wrong? →